| abstract |
The present invention relates to compounds of formula (I) or (II) wherein R1 is hydrogen, alkyl, alkenyl, aryl, arylalkyl, hydroxyalkyl, haloalkyl, alkoxy, COR10, CONR10R11 OR10, S (O) mR10, NR10COR11 or NR10R11, wherein or when X is NR11, R1 may be carboxyalkyl; R6 is hydrogen, alkyl, alkenyl, aryl, arylalkyl, R2 and R7 are hydrogen, halogen, trifluoromethyl, nitro, cyano, alkyl, aryl, arylalkyl, alkenyl, COR10; CONR10R11, R3 is hydrogen, alkyl, aryl or arylalkyl, A is alkyl or substituted alkyl, m is 0-2 and n is 1-3, Y is O, NR11 or S, X is O, NR11 or S, R4, R5 , R8 and R9 are independently tetrazolyl, oxa and thiadiazolyl, or oxopyridazinyl, or when X is NR11, R4, R5, R8 and R9 may independently be HOOC, R12OOC, H2NCO or HOHNCO, and each aryl residue, alone or as part of another group, may be optionally substituted - and pharmaceutically acceptable salts and esters thereof for use in the treatment of heart failure due to their phospholambane inhibitory activity. The invention also relates to the intermediate of formula (XXV). SHE |